CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 39 enrolled
Drug / intervention
Dasatinibdrug
Likely dose
Dasatinib 100 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01660906
NCT01660906Phase 4Completed
CompareCT.gov

A Phase IV, Open-label, Multicenter Study of Dasatinib in Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients With Chronic, Low-grade Non-Hematologic Toxicity to Imatinib

Bristol-Myers Squibb·interventional·Posted Aug 9, 2012·Updated Nov 22, 2016

In Brief

A Phase 4 clinical trial evaluating Dasatinib for Chronic Phase Chronic Myeloid Leukemia. Completed, enrolled 39 participants across 22 sites in 5 countries.

Detailed Summary

This study proposes to evaluate the number of chronic, Grade 1 or 2, non-hematologic Adverse Events (AEs) that reduce in grade or resolve at 3 months after switching therapy from imatinib to dasatinib.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Phase Chronic Myeloid Leukemia
CountriesFrance, Germany, Italy, South Korea, United States
Collaborators--

Timeline

Phase 4CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedAug 9, 2012
Enrollment StartDec 1, 2012
Primary CompletionOct 1, 2015
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 13.9 years ago

Interventions

Dasatinibdrug

tablets, oral, 100 mg, Once daily, Up to12 months on study,